4.7 Editorial Material

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England Comment

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

Nick Andrews et al.

Summary: This study examined the relative and absolute effectiveness of mRNA booster vaccination against COVID-19. The results showed that the booster dose of BNT162b2 or mRNA-1273 had a relative effectiveness ranging from 85% to 95% against symptomatic disease, and an absolute effectiveness ranging from 94% to 97%. For hospitalization or death, the absolute effectiveness of the BNT162b2 booster ranged from 97% to 99% in all age groups. The study provides real-world evidence of significantly increased protection from the booster vaccine dose against mild and severe disease.

NATURE MEDICINE (2022)

Article Medicine, General & Internal

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Nick Andrews et al.

Summary: A study conducted in England showed that vaccines against SARS-CoV-2 provide high protection against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. However, the effectiveness of the vaccines decreases over time, especially in individuals aged 65 and older and those with underlying risk factors.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, General & Internal

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Hiam Chemaitelly et al.

Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)